Trial Profile
A Phase I Pilot Study of Immunotherapy Using Lenalidomide Plus 'Bystander' Vaccine in Patients With High-Risk Myelodysplastic Syndrome (MDS).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs CD40L GVAX (Primary) ; Lenalidomide (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- 10 Dec 2019 Status changed from active, no longer recruiting to completed.
- 03 Jul 2019 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.
- 30 Apr 2018 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.